Key Points CONMED shares dove 10% last week, retreating below the $100.00 level in an apparent bout of profit taking on one of the market’s hottest groups. The company is expected to have generated approximately$332 million in fourth quarter sales with EPS forecast to jump 164% year-over-year to $1.11. Even if the "Ozempic effect" is large, it will likely have an insignificant impact on CONMED’s overall financial results since the company provides products for many procedures other than bariatric surgery. ...